$0.77
(Market cap
$6,940 Mln
Recently Viewed
Clear AllMarket cap
$6,940 Mln
Revenue (TTM)
$507 Mln
P/E Ratio
--
P/B Ratio
10.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-57.9
Debt to Equity
0.2
Book Value
$11.4
EPS
$-3.3
Face value
--
Shares outstanding
58,078,812
CFO
$-42.10 Mln
EBITDA
$-439.10 Mln
Net Profit
$-446.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Glaukos Corp (GKOS)
| 8.8 | 21.7 | -1.0 | 39.2 | 35.3 | 6.3 | 21.2 |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Glaukos Corp (GKOS)
| -24.7 | 87.7 | 82.0 | -1.7 | -41.0 | 38.2 | -3.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Glaukos Corp (GKOS)
|
122.9 | 6,939.8 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.6 |
| 8.4 | 5,633.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 1.0 | |
| 277.0 | 7,476.3 | 2,583.2 | 759.9 | 25.2 | 10.8 | 9.9 | 1.0 | |
| 39.6 | 6,195.5 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.4 | |
| 27.5 | 4,414.8 | 2,719.5 | 47.0 | 8.4 | 1.6 | 96.2 | 1.4 | |
| 82.1 | 5,456.9 | 1,541.6 | 233.6 | 21.6 | 21.4 | 24.6 | 5.0 | |
| 178.4 | 9,341.0 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.6 | 12.9 | |
| 333.5 | 12,941.2 | 1,403.7 | 177.7 | 14.7 | 13.8 | 73 | 9.1 | |
| 130.6 | 7,400.2 | 738.3 | 48.9 | 11.4 | 2.4 | 150.8 | 3.5 | |
| 32.7 | 14,139.4 | 6,178.4 | 626.5 | 13.0 | 11.9 | 23.2 | 2.6 |
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W... micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. Address: One Glaukos Way, Aliso Viejo, CA, United States, 92656 Read more
Chairman & CEO
Mr. Thomas William Burns
Chairman & CEO
Mr. Thomas William Burns
Headquarters
Aliso Viejo, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Glaukos Corp (GKOS) is $122.88 (NYSE) as of 22-Apr-2026 10:44 EDT. Glaukos Corp (GKOS) has given a return of 35.34% in the last 3 years.
Since, TTM earnings of Glaukos Corp (GKOS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-34.59
|
9.90
|
|
2024
|
-56.94
|
10.87
|
|
2023
|
-28.85
|
8.41
|
|
2022
|
-21.02
|
3.93
|
|
2021
|
-42.05
|
3.55
|
The 52-week high and low of Glaukos Corp (GKOS) are Rs 130.23 and Rs 73.16 as of 22-Apr-2026.
Glaukos Corp (GKOS) has a market capitalisation of $ 6,940 Mln as on 14-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Glaukos Corp (GKOS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.